Physician profile
Lance A Sloan
NPI 1588665228
$1,742,301.81
in general payments reported to CMS, 2019-2025
78 companies · $236K in 2025
The $236K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $457K · 2020: $172K · 2021: $203K · 2022: $128K · 2023: $186K · 2024: $360K · 2025: $236K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $576K · Travel and Lodging: $96K · Consulting Fee: $54K · Food and Beverage: $32K · Honoraria: $24K · Education: $59.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $575,796.59 |
| Travel and Lodging | $96,185.86 |
| Consulting Fee | $53,929.50 |
| Food and Beverage | $32,172.58 |
| Honoraria | $24,335.00 |
| Education | $59.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $519,625.02 | 2019-2025 | Farxiga, Lokelma |
| Lilly USA, LLC | $366,696.58 | 2019-2025 | Zepbound, Jardiance, Baqsimi |
| Corcept Therapeutics | $192,363.02 | 2019-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188,648.22 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $134,121.54 | 2019-2022 | |
| Pfizer INC. | $54,422.19 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $46,439.32 | 2019-2023 | Verquvo, Steglatro |
| Glaxosmithkline, LLC. | $42,657.14 | 2022-2024 | Jesduvroq, Benlysta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $33,401.01 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $28,327.90 | 2019-2025 | |
| Novo Nordisk INC | $28,090.04 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Eli Lilly and Company | $18,562.78 | 2019-2025 | |
| Abbott Laboratories | $12,765.64 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Janssen Scientific Affairs, LLC | $12,696.30 | 2019-2024 | Xarelto |
| Rockwell Medical, INC. | $11,736.25 | 2019 |
Show all 74 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $8,264.80 | 2023-2025 | Yorvipath |
| Novo Nordisk As | $7,677.67 | 2022-2024 | |
| Boehringer Ingelheim International Gmbh | $7,271.26 | 2019-2022 | |
| Travere Therapeutics, INC. | $6,302.03 | 2023-2025 | Filspari |
| Gilead Sciences, INC. | $4,571.49 | 2019 | |
| Idorsia Pharmaceuticals US INC | $4,200.97 | 2024-2025 | Tryvio, Tryvio |
| Madrigal Pharmaceuticals | $4,045.66 | 2025 | Rezdiffra |
| Amgen INC. | $2,080.45 | 2019-2025 | Tepezza, Evenity, Tavneos |
| Amarin Pharma, INC. | $897.06 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $783.06 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $708.02 | 2022-2025 | |
| Dexcom, INC. | $607.01 | 2021-2024 | Dexcom G6 Transmitter |
| Medtronic, INC. | $487.88 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Radius Health, INC. | $324.30 | 2019-2024 | Tymlos |
| Lexicon Pharmaceuticals, INC. | $302.75 | 2019-2024 | |
| Insulet Corporation | $255.41 | 2022-2025 | Omnipod |
| Ionis Pharmaceuticals, INC. | $241.51 | 2025 | Tryngolza |
| Esperion Therapeutics, INC. | $202.15 | 2020-2024 | Nexletol |
| Medicure Pharma INC. | $199.18 | 2020 | |
| Calliditas Therapeutics US INC. | $184.72 | 2023-2025 | Tarpeyo |
| Scpharmaceuticals INC. | $145.53 | 2024-2025 | |
| Horizon Therapeutics Plc | $131.50 | 2020-2023 | Tepezza |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $123.20 | 2022 | |
| Abbvie INC. | $121.49 | 2022-2025 | |
| Medtronic Minimed, INC. | $120.92 | 2019-2020 | |
| Mylan INC. | $119.82 | 2020 | |
| Endo Pharmaceuticals INC. | $80.41 | 2020-2021 | |
| Recordati_rare_diseases_inc. | $75.83 | 2024-2025 | Isturisa, Signifor Lar |
| Tandem Diabetes Care, INC. | $72.24 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ardelyx, INC. | $70.80 | 2025 | Ibsrela |
| Genentech USA, INC. | $66.21 | 2025 | Gazyva |
| Recor Medical INC | $65.46 | 2025 | Paradise Ultrasound Renal Denervation System |
| Ultragenyx Pharmaceutical INC. | $65.23 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $63.64 | 2020-2022 | |
| Amryt Pharma Holdings Ltd | $61.58 | 2022-2023 | Myalept |
| Nevro Corp. | $61.56 | 2022-2024 | Senza |
| Vifor Pharma, INC. | $58.49 | 2021-2023 | Veltassa |
| Covidien Lp | $48.79 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.41 | 2020 | |
| Ani Pharmaceuticals, INC. | $43.30 | 2023 | Purified Cortrophin Gel |
| Ascensia Diabetes Care US INC. | $43.01 | 2025 | |
| Beta Bionics, INC. | $39.51 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Antares Pharma, INC. | $38.54 | 2024-2025 | Xyosted |
| Ibsa Pharma INC. | $38.45 | 2021-2023 | Tirosint, Licart |
| Intuity Medical INC | $36.94 | 2022 | |
| Genzyme Corporation | $32.55 | 2024 | |
| Cormedix INC. | $27.74 | 2024 | Defencath |
| Enterra Medical, INC. | $27.43 | 2023 | |
| Paratek Pharmaceuticals, INC. | $25.22 | 2021 | |
| Fresenius USA Marketing, INC. | $24.30 | 2025 | Nxstage System One |
| Regeneron Healthcare Solutions, INC. | $23.14 | 2023 | Evkeeza, Praluent |
| Halozyme INC | $21.27 | 2023 | |
| Kyowa Kirin, INC. | $21.03 | 2023 | |
| Alexion Pharmaceuticals, INC. | $20.12 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $19.71 | 2022 | |
| Globus Medical, INC. | $17.18 | 2025 | Senza |
| Cequr Corporation | $16.88 | 2025 | Cequr Simplicity |
| Shire North American Group INC | $14.64 | 2019 | |
| Companion Medical, INC. | $14.41 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$31,871.29 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Sloan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.